A trading update for the year ending 31 March 2018 indicates revenues to be c.£1m lower than expected at £13.6m, resulting in an adjusted pre-tax loss of c.£0.7m versus our pre-tax profit forecast of £0.5m. A strategic review of the business by the new CEO has led to the decision to withdraw from its German Allergy business and manufacturing facility in Pune India, which had a combined LBITDA of c.£0.8m in FY 2018. Together with a legal simplification of its UK b
10 Apr 2018
Trading update and strategic review
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Trading update and strategic review
Cambridge Nutritional Sciences PLC (CNSL:LON) | 4.0 0 8.1% | Mkt Cap: 9.52m
- Published:
10 Apr 2018 -
Author:
Mark Brewer -
Pages:
10
A trading update for the year ending 31 March 2018 indicates revenues to be c.£1m lower than expected at £13.6m, resulting in an adjusted pre-tax loss of c.£0.7m versus our pre-tax profit forecast of £0.5m. A strategic review of the business by the new CEO has led to the decision to withdraw from its German Allergy business and manufacturing facility in Pune India, which had a combined LBITDA of c.£0.8m in FY 2018. Together with a legal simplification of its UK b